Sign in
Taking peoplePhase 4

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

Key facts

Who runs it
Todd C. Lee MD MPH FIDSA
Where
Canada3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
300 people, planned
Started
23 Feb 2026
Expected to end
Jan 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Clopidogrel
  • Aspirin
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Patient is taking (or will imminently start) aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)

Who cannot take part

  • Concomitant receipt of an oral factor Xa inhibitor (apixaban, rivaroxaban, or edoxaban) or dabigatran
  • Active bleeding (allowing up to 120 hours from platform entry to randomize in the event anti-thrombotic therapy is resumed)
  • Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days
  • Allergy to clopidogrel
  • Pregnancy or lactation
  • Known receipt of clopidogrel, prasugrel, or ticagrelor within the last month

Other criteria

  • The participant must meet all inclusion and exclusion criteria for the SNAP
  • Platform (NCT05137119) and also the following inclusion and exclusion criteria:

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Staphylococcus aureus endocarditis or staphylococcus aureus septicemia or staphylococcus aureus bloodstream infection

This trial is currently available in Canada.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention.

Read full original descriptionShow less

Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).

If positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.

The 2 groups in the trial

  • Change to clopidogrel 75mg per dayTreatment being tested

    Patients will have their aspirin discontinued and start clopidogrel.

    Treatment: Clopidogrel

  • Continue aspirinExisting treatment, for comparison

    Patients will continue their existing aspirin

    Treatment: Aspirin

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06650488, who can take part
Record updated
17 November 2026